Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of advancing doses of curcuminoids
administered orally for fourteen consecutive days in adult subjects with cystic fibrosis (CF)
who are homozygous for ΔF508 CFTR.
Phase:
Phase 1
Details
Lead Sponsor:
Ramsey, Bonnie, MD
Collaborators:
CF Therapeutics Development Network Coordinating Center Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics Seer Pharmaceuticals